Levetiracetam for management of seizures in newborn

Levetiracetam in neonatal seizures -a randomised study

Status

Recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2013/04/003585

Enrollment

100

Registered

2013-04-26

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- neonatal seizure

Interventions

Intervention1: levetiracetam: control of seizures Intervention2: phenobarbitone: 20 mg/kg as loading dose followed by 5 mg/kg /day maintenance in two divided doses,continued till baby is seizure free

Eligibility

Inclusion criteria

Inclusion criteria: Babies admitted to NICU with seizures and babies having seizures during NICU stay with • Gestational age >= 30 wks Birth weight >= 1.5 kg Clinical or electrographic seizures Parental consent obtained

Exclusion criteria

Exclusion criteria: Babies with renal serum creatinine > 2.0 Birth at < 30 weeks gestation Parents refuse consent

Design outcomes

Primary

Measure	Time frame
To study the therapeutic benefit of levetiracetum in neonatal seizures and to compare efficacy with other antiseizure medication.Timepoint: 30/06/2013	—

Secondary

Measure	Time frame
use of leviteracetam in various types of neonatal seizuresTimepoint: 30/6/2013	—

Countries

India

Contacts

Public ContactDr Venkatlakshmi

Rainbow Childrenâ??s Hospital

rabindranindia@yahoo.co.in8712307790

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026